About Us Our Business Products Investor Relations Distributors / Dealers Contact Document request

INFORMATION RETRIEVAL

top page

  • Home
  • Investor Relations

What's new

2012/7/19 IBL-Japan and IBL-Int’l sign a Collaboration and License Agreement for Commercializing of IVD Products in the field of Alzheimer’s disease
2012/6/11 Immuno-Biological Laboratories Co., Ltd. and ADx NeuroSciences N.V. sign a Collaborative Research and Development Agreement in the field of Alzheimer's disease (Translation only - Press Release made in Japan)
2012/1/30 Immuno-Biological Laboratories Co., Ltd. and Takara Bio Inc. enter to sign a
distribution agreement for IBL research use only (RUO) products.
   

Dear Stockholders

We are sure that Immuno-Biological Laboratories Co., Ltd. has been contributing to human health by supplying various research reagents and clinical reagents for cancer research as well as research reagents for inflammatory cytokines, growth factors, and antibodies for use against those proteins. Continuously we keep working on the development of immuno-diagnosis for intractable diseases based on the accumulated technical know-how acquired through the experiences of antibody production. In addition to the existing business, we create transgenic animals and analyze genes and proteins from such animals seeking new targets for drug discovery. Having antibody-production technologies as our core technologies, we will continue to supply products which meet the needs of the growing life science community and increase our corporate value.

清藤 勉
Please contact from a contacting form here Support.